Genzyme, Fovea sign blindness therapy deal

Genzyme and Paris-based Fovea Pharmaceuticals have forged a collaboration to develop gene therapies for blindness. The cross-Atlantic pact will match Genzyme's expertise in protein production and gene delivery with Fovea's expertise in retinal disease. They hope to advance new gene therapies for photoreceptor degeneration, a prime cause of blindness. No financial terms were disclosed. Fovea was launched two years ago.

"This first research partnership signed with Genzyme demonstrates the interest of our proprietary discovery platform," said Bernard Gilly, chairman and CEO of Fovea.

- see this release
- here's the report from the Boston Business Journal

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.